73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Gilead Sciences Inc.
Closed
SectorHealthcare
124.03 1.9
Overview
Share price change
24h
Min
121.34
Max
124.09
Income | 1.1B 3.1B |
|---|---|
Sales | 688M 7.8B |
P/E Sector Avg | 18.978 90.831 |
Dividend yield | 2.59 |
Profit margin | 39.284 |
Employees | 17,600 |
EBITDA | 1.2B 4.6B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +10.46% upside |
Dividend yield Sector Avg | 2.59% 2.20% |
|---|---|
Next Earnings | 10 Feb 2026 |
Next Dividend date | 27 Mar 2026 |
Next Ex Dividend date | 13 Mar 2026 |
Market Cap | 2.1B 152B |
|---|---|
Previous open | 122.13 |
Previous close | 124.03 |
News Sentiment
By Acuity
33%
67%
68 / 361 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Gilead Sciences Inc. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Gilead Sciences Inc. Forecast
Price Target
By TipRanks
10.46% upside
12 Months Forecast
Average 135.43 USD 10.46%
High 150 USD
Low 100 USD
Based on 19 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.
Sentiment
By Acuity
68 / 361 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Gilead Sciences Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Live chat